Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0000499
UniProt IDP20248
Primary gene name(s)CCNA2
Synonym gene name(s)CCN1, CCNA
Protein nameCyclin-A2
Protein functionEssential for the control of the cell cycle at the G1/S, start and the G2/M, mitosis transitions.
Subcellular locationNucleus {ECO:0000269|PubMed:17698606}. Cytoplasm {ECO:0000269|PubMed:17698606}. Note=Cytoplasmic when associated with SCAPER.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P20248
Gene Ontology
(Biological Process)
Complete annatation
animal organ regeneration [GO:0031100];
cell division [GO:0051301];
cellular response to cocaine [GO:0071314];
cellular response to estradiol stimulus [GO:0071392];
cellular response to hypoxia [GO:0071456];
cellular response to insulin-like growth factor stimulus [GO:1990314];
cellular response to leptin stimulus [GO:0044320];
cellular response to luteinizing hormone stimulus [GO:0071373];
cellular response to nitric oxide [GO:0071732];
cellular response to platelet-derived growth factor stimulus [GO:0036120];
cochlea development [GO:0090102];
G2/M transition of mitotic cell cycle [GO:0000086];
mitotic nuclear division [GO:0007067];
positive regulation of fibroblast proliferation [GO:0048146];
positive regulation of transcription, DNA-templated [GO:0045893];
Ras protein signal transduction [GO:0007265];
regulation of cyclin-dependent protein serine/threonine kinase activity [GO:0000079];
regulation of G2/M transition of mitotic cell cycle [GO:0010389];
regulation of mitotic cell cycle DNA replication [GO:1903463];
response to glucagon [GO:0033762];
viral process [GO:0016032]
Gene Ontology
(Molecular Function)
Complete annatation
Gene Ontology
(Cellular Component)
Complete annatation
cytoplasm [GO:0005737];
female pronucleus [GO:0001939];
Golgi apparatus [GO:0005794];
male pronucleus [GO:0001940];
nucleoplasm [GO:0005654];
nucleus [GO:0005634]
Protein-protein interaction107331
Phylogenetic treeP20248
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD30.8681547663224550.5138361936261410.62948379341081
AZA vs. DISU-0.3289979515861080.4713668190166760.926405371176645
AZA vs. IL70.1561956578586770.761409922823550.999311006273513
AZA vs. SAHA-0.5384809235301110.1683353045561830.523300965328915
DISU vs. CD3-1.20782206598220.3562693801024310.490000422962048
DISU vs. IL70.4753875925648450.3675292798990090.743029356509
DISU vs. SAHA-0.2097105106903340.6085473969166650.87683917551558
DMSO vs. AZA-0.08783637388823950.8235106516172061
DMSO vs. CD3-0.967571757667340.4694264116399690.580162154538677
DMSO vs. DISU0.2385684764482590.5607401189596920.925732173460781
DMSO vs. IL70.2512650856343230.5976505240841420.911970258876874
DMSO vs. SAHA-0.458232486872920.1679270719129180.495269843600702
HIV vs. Mock in Activation-0.1305420476707690.9537295286365070.999983755607037
HIV vs. Mock in Latency0.4330175382175970.3403312764515710.999834320637052
IL7 vs. CD3-0.7033348753334430.5904018314927270.708352842583868
SAHA vs. CD3-1.432421469206660.2872202859392680.400407928686842
SAHA vs. IL7-0.697542138170430.1435308984274220.357381031201677
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change -1.107842216
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
2.2 0.000852056 1.3 0.105970905 1.4 0.027832302
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) FALSE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.425745 0.00108419
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
0.047 5.97E-04

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
1.145 1.584 1.462 1.216 1.186
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
213226_at 1.69 Yes upregulated in CD4+ cells
213226_at 2.85 Yes upregulated in CD8+ cells

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB06844 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE experimental unknown unknown
DB06944 N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide experimental unknown unknown
DB06948 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE experimental unknown unknown
DB07126 O6-CYCLOHEXYLMETHOXY-2-(4&,39;-SULPHAMOYLANILINO) PURINE experimental unknown unknown
DB07137 (2S)-N-[(3Z)-5-CYCLOPROPYL-3H-PYRAZOL-3-YLIDENE]-2-[4-(2-OXOIMIDAZOLIDIN-1-YL)PHENYL]PROPANAMIDE experimental unknown unknown
DB07164 N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine experimental unknown unknown
DB07203 6-CYCLOHEXYLMETHOXY-2-(3&,39;-CHLOROANILINO) PURINE experimental unknown unknown
DB07533 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE experimental unknown unknown
DB07534 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE experimental unknown unknown
DB07539 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID experimental unknown unknown
DB02091 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine experimental unknown unknown
DB02915 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(4-Trifluoromethyl-Phenyl)-Amine experimental unknown unknown
DB02833 [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine experimental unknown unknown
DB07562 N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N&,39;,N&,39;-DIMETHYL-BENZENE-1,4-DIAMINE experimental unknown unknown
DB02407 6-O-Cyclohexylmethyl Guanine experimental unknown unknown
DB07688 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE experimental unknown unknown
DB07852 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID experimental unknown unknown
DB08178 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine experimental unknown unknown
DB08182 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine experimental unknown unknown
DB08218 HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM experimental unknown unknown
DB08219 4-METHYL-5-{(2E)-2-[(4-MORPHOLIN-4-YLPHENYL)IMINO]-2,5-DIHYDROPYRIMIDIN-4-YL}-1,3-THIAZOL-2-AMINE experimental unknown unknown
DB08233 6-CYCLOHEXYLMETHYLOXY-2-(4&,39;-HYDROXYANILINO)PURINE experimental unknown unknown
DB08241 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE experimental unknown unknown
DB08285 (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol experimental unknown unknown
DB08309 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL experimental unknown unknown
DB08355 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid experimental unknown unknown
DB08463 (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol experimental unknown unknown
DB08527 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE experimental unknown unknown
DB08694 9-amino-5-(2-aminopyrimidin-4-yl)pyrido[3&,39;,2&,39;:4,5]pyrrolo[1,2-c]pyrimidin-4-ol experimental unknown unknown

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1E9H X-ray 2.5Å B/D=175-432.
1FIN X-ray 2.3Å B/D=173-432.
1FVV X-ray 2.8Å B/D=173-432.
1GY3 X-ray 2.7Å B/D=175-432.
1H1P X-ray 2.1Å B/D=175-432.
1H1Q X-ray 2.5Å B/D=175-432.
1H1R X-ray 2.0Å B/D=175-432.
1H1S X-ray 2.0Å B/D=175-432.
1H24 X-ray 2.5Å B/D=174-432.
1H25 X-ray 2.5Å B/D=174-432.
1H26 X-ray 2.2Å B/D=174-432.
1H27 X-ray 2.2Å B/D=174-432.
1H28 X-ray 2.8Å B/D=174-432.
1JST X-ray 2.6Å B/D=175-432.
1JSU X-ray 2.3Å B=173-432.
1OGU X-ray 2.6Å B/D=174-432.
1OI9 X-ray 2.1Å B/D=174-432.
1OIU X-ray 2.0Å B/D=174-432.
1OIY X-ray 2.4Å B/D=174-432.
1OKV X-ray 2.4Å B/D=173-432.
1OKW X-ray 2.5Å B/D=173-432.
1OL1 X-ray 2.9Å B/D=173-432.
1OL2 X-ray 2.6Å B/D=173-432.
1P5E X-ray 2.2Å B/D=175-432.
1PKD X-ray 2.3Å B/D=175-432.
1QMZ X-ray 2.2Å B/D=174-432.
1URC X-ray 2.6Å B/D=173-432.
1VYW X-ray 2.3Å B/D=174-432.
2BKZ X-ray 2.6Å B/D=174-432.
2BPM X-ray 2.4Å B/D=174-432.
2C4G X-ray 2.7Å B/D=173-432.
2C5N X-ray 2.1Å B/D=174-432.
2C5O X-ray 2.1Å B/D=173-432.
2C5V X-ray 2.9Å B/D=174-432.
2C5X X-ray 2.9Å B/D=174-432.
2C6T X-ray 2.6Å B/D=175-432.
2CCH X-ray 1.7Å B/D=173-432.
2CCI X-ray 2.7Å B/D=175-432.
2CJM X-ray 2.3Å B/D=175-432.
2I40 X-ray 2.8Å B/D=173-432.
2IW6 X-ray 2.3Å B/D=174-432.
2IW8 X-ray 2.3Å B/D=174-432.
2IW9 X-ray 2.0Å B/D=174-432.
2UUE X-ray 2.0Å B/D=174-432.
2UZB X-ray 2.7Å B/D=175-432.
2UZD X-ray 2.7Å B/D=175-432.
2UZE X-ray 2.4Å B/D=175-432.
2UZL X-ray 2.4Å B/D=175-432.
2V22 X-ray 2.6Å B/D=174-432.
2WEV X-ray 2.3Å B/D=173-432.
2WFY X-ray 2.5Å B/D=173-432.
2WHB X-ray 2.9Å B/D=173-432.
2WIH X-ray 2.5Å B/D=173-432.
2WIP X-ray 2.8Å B/D=173-432.
2WMA X-ray 2.8Å B/D=174-432.
2WMB X-ray 2.6Å B/D=174-432.
2WPA X-ray 2.5Å B/D=173-432.
2WXV X-ray 2.6Å B/D=173-432.
2X1N X-ray 2.7Å B/D=172-432.
3EID X-ray 3.1Å B/D=173-432.
3EJ1 X-ray 3.2Å B/D=173-432.
3EOC X-ray 3.2Å B/D=173-432.
3F5X X-ray 2.4Å B/D=177-432.
4BCK X-ray 2.0Å B/D=171-432.
4BCM X-ray 2.4Å B/D=171-432.
4BCN X-ray 2.1Å B=171-432# D=171-431.
4BCP X-ray 2.2Å B/D=171-432.
4CFM X-ray 2.8Å B/D=175-432.
4CFN X-ray 2.2Å B/D=175-432.
4CFU X-ray 2.2Å B=172-432# D=173-432.
4CFV X-ray 2.0Å B/D=172-432.
4CFW X-ray 2.4Å B/D=175-432.
4CFX X-ray 3.5Å B/D=173-432.
4EOI X-ray 2.0Å B/D=175-432.
4EOJ X-ray 1.6Å B/D=175-432.
4EOK X-ray 2.5Å B/D=175-432.
4EOL X-ray 2.4Å B/D=175-432.
4EOM X-ray 2.1Å B/D=175-432.
4EON X-ray 2.4Å B/D=175-432.
4EOO X-ray 2.1Å B/D=175-432.
4EOP X-ray 1.9Å B/D=175-432.
4EOQ X-ray 2.1Å B/D=175-432.
4EOR X-ray 2.2Å B/D=175-432.
4EOS X-ray 2.5Å B/D=175-432.
4FX3 X-ray 2.7Å B/D=175-432.
5CYI X-ray 2.0Å B/D=174-432.
5IF1 X-ray 2.6Å B/D=174-432.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Tat interacts with 15050687

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa04110 Cell cycle - Homo sapiens (human)
hsa04152 AMPK signaling pathway - Homo sapiens (human)
hsa04914 Progesterone-mediated oocyte maturation - Homo sapiens (human)
hsa05161 Hepatitis B - Homo sapiens (human)
hsa05169 Epstein-Barr virus infection - Homo sapiens (human)
hsa05203 Viral carcinogenesis - Homo sapiens (human)